• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Brazilian Journal of Microbiology >Efficacy of terbinafine and itraconazole on a experimental model of systemic sporotrichosis
【2h】

Efficacy of terbinafine and itraconazole on a experimental model of systemic sporotrichosis

机译：特比萘芬和伊曲康唑在全身性孢子体增生实验模型中的功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Itraconazole is currently considered the drug of choice to treat the diverse clinical presentation of sporotrichosis. On the other hand terbinafine by virtue of its excellent in vitro activity is under comparative evaluation for its therapeutic potential for a wide range of fungal infections. In this study, our aim was to determine the in vivo efficacy of terbinafine and itraconazole on a experimental model of systemic sporotrichosis. 120 rats Wistar received an injection of 2×103 S. schenckii cells by via the lateral tail vein. After 3 days the animals were treated with terbinafine (250mg/kg) and itraconazole (100 mg/kg) and their respective diluents. In our model, terbinafine and itraconazole were effective in reducing the number of clinical lesions and positive organ cultures. There was statistical difference between the groups treated with the antifungals in relation to the control groups (p<0,05) concerning the clinical alterations, anatomic-pathological findings and in the positive organ cultures of the agent, being that the treated animals resulted in the absence and/or reduction of all the evaluated parameters. As for the treatments, terbinafine showed similar or higher activity that itraconazole in the evaluation of the testicle alteration (p=0,0004), as well as in the positive organ cultures of microorganism from the organ (p=0,0142). With these results it is possible to conclude that the antifungals studied are effective in the treatment of experimental systemic sporotrichosis.
机译：伊曲康唑目前被认为是治疗孢子体病的各种临床表现的首选药物。另一方面，由于特比萘芬具有优异的体外活性，因此其对多种真菌感染的治疗潜力正在接受比较评估。在这项研究中，我们的目的是确定特比萘芬和伊曲康唑在全身性孢子体增生实验模型上的体内疗效。 Wistar经侧尾静脉注射120只大鼠，注射了2×10 3 申氏链球菌。 3天后，用特比萘芬（250mg / kg）和伊曲康唑（100mg / kg）及其各自的稀释剂处理动物。在我们的模型中，特比萘芬和伊曲康唑可有效减少临床病变和阳性器官培养的数量。在抗真菌药治疗组之间，相对于对照组（p <0.05），在临床改变，解剖病理学发现和药物的阳性器官培养方面存在统计学差异（p <0.05），这是由于治疗动物导致所有评估参数的缺失和/或减少。至于治疗，特比萘芬在评估睾丸改变（p = 0,0004）以及来自器官的微生物的阳性器官培养物中显示出与伊曲康唑相似或更高的活性（p = 0,0142）。根据这些结果，可以得出结论，所研究的抗真菌药可有效治疗实验性系统性孢子体病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号